Zevra Therapeutics Cash Flow Statement
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.39+0.39 (+3.55%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zevra Therapeutics free cash flow
In fiscal 2025, Zevra Therapeutics generated -$1.6 million of operating cash flow and spent $835,000 on capital expenditures. That left free cash flow of -$2.4 million, a free-cash-flow margin of -2.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Zevra Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 83.23M | -105.51M | -46.05M | -26.77M | -8.55M | -12.76M | -24.52M | -56.47M | -43.39M | -16.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.05M | 6.39M | 1.01M | 944.00K | 257.00K | 273.00K | 304.00K | 324.00K | 336.00K | 175.00K |
| Stock-Based Compensation | 12.63M | 14.91M | 5.95M | 4.29M | 2.44M | 2.49M | 4.41M | 6.50M | 4.56M | 6.60M |
| Change in Working Capital | -31.81M | -7.83M | 2.41M | -4.39M | -887.00K | 377.00K | -4.97M | -2.18M | -1.73M | 3.14M |
| Operating Cash Flow | -1.60M | -69.67M | -33.53M | -18.72M | 10.44M | -1.94M | -23.74M | -54.20M | -33.10M | -29.77M |
| Capital Expenditures | -835.00K | 0 | -296.00K | -93.00K | -102.00K | -33.00K | -26.00K | -21.00K | -181.00K | -643.00K |
| Investing Cash Flow | 18.13M | -22.16M | -17.39M | -36.72M | -15.52M | -33.00K | 3.23M | 33.33M | 27.41M | -45.85M |
| Share Repurchases | — | 0 | -3.45M | -4.72M | -2.81M | 0 | — | — | — | — |
| Debt Issued | 0 | 58.99M | 42.43M | 12.80M | 0 | 781.00K | — | — | — | 82.80M |
| Debt Repaid | 0 | -42.70M | -17.53M | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 12.06M | 82.11M | 28.46M | 8.35M | 113.11M | 2.74M | 4.94M | 28.02M | -203.00K | 61.16M |
| Net Change in Cash | 28.62M | -9.26M | -22.42M | -46.88M | 108.02M | 767.00K | -15.56M | 7.15M | -5.89M | -14.46M |
| Free Cash Flow | -2.43M | -69.67M | -33.83M | -18.81M | 10.34M | -1.97M | -23.76M | -54.22M | -33.28M | -30.41M |
This table shows 10 annual periods of Zevra Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZVRA's reporting calendar. What is a cash flow statement?